Trials / Completed
CompletedNCT01383135
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study was to conduct a pilot test of new tracers (\[18F\]FPRGD2 and \[18F\]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much stays in which organs and for how long), and radiation dosimetry (organ radiation dose). Healthy volunteers provided the normal biodistribution data. The same radiopharmaceutical was also tested in breast cancer, glioblastoma multiform (brain cancer), and lung cancer.
Detailed description
The tracer \[18F\]FPRGD2 was not evaluated in this study. The protocol title was never amended to reflect this.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F18-FPPRGD2 | Radiopharmaceutical administered for imaging, up to 14 mCi intravenous (IV). |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2012-04-01
- Completion
- 2013-12-01
- First posted
- 2011-06-28
- Last updated
- 2024-01-12
- Results posted
- 2024-01-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01383135. Inclusion in this directory is not an endorsement.